Nautilus Biotechnology
E523160
Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Nautilus Biotechnology canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5465251 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Nautilus Biotechnology Context triple: [Avie Tevanian, boardMemberOf, Nautilus Biotechnology]
-
A.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
B.
Nanosphere, Inc.
Nanosphere, Inc. was a biotechnology company specializing in nanoparticle-based molecular diagnostic tests for detecting genetic and infectious diseases.
-
C.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
D.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
E.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Nautilus Biotechnology Target entity description: Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
-
A.
Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on developing treatments and prophylactics for serious infectious diseases using antibody, T cell, and other immune-based technologies.
-
B.
Nanosphere, Inc.
Nanosphere, Inc. was a biotechnology company specializing in nanoparticle-based molecular diagnostic tests for detecting genetic and infectious diseases.
-
C.
Insitro
Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
-
D.
Array BioPharma
Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
-
E.
Verily Life Sciences LLC
Verily Life Sciences LLC is a health-focused research and technology company that develops tools and platforms to collect, organize, and analyze health data, particularly in areas like clinical research, precision health, and disease management.
- F. None of above. chosen
Statements (31)
| Predicate | Object |
|---|---|
| instanceOf |
biotechnology company
ⓘ
proteomics company ⓘ |
| aimsTo |
accelerate drug discovery
ⓘ
enable comprehensive analysis of the human proteome ⓘ support biomedical research ⓘ |
| develops |
high-throughput proteomics platforms
ⓘ
next-generation proteomics platforms ⓘ platforms for comprehensive proteome analysis ⓘ |
| focusesOn |
drug discovery applications
ⓘ
human proteome analysis ⓘ proteomics ⓘ research applications ⓘ |
| goal |
enable large-scale proteomic studies
ⓘ
improve sensitivity of protein detection ⓘ improve throughput of proteomics experiments ⓘ increase depth of proteome coverage ⓘ |
| hasApplicationIn |
biomedical research
ⓘ
drug discovery ⓘ |
| industry |
biotechnology
ⓘ
life sciences ⓘ proteomics ⓘ |
| offers | proteomics platform ⓘ |
| serves |
academic research institutions
ⓘ
biotechnology companies ⓘ drug discovery researchers ⓘ pharmaceutical companies ⓘ |
| subjectArea |
human proteome
ⓘ
protein biology ⓘ systems biology ⓘ |
| technologyType |
high-throughput analysis
ⓘ
proteome-wide measurement ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Nautilus Biotechnology Description of subject: Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.